71 results
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
Fabry disease patients, symptomatic female carriers
I/C
X chromosome inactivation analysis, correlation between XCI and symptoms/phenotype
O
manifesting Fabry carriers, Mainz Severity Score Index, cardiac involvement
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
Yu X, Xu R, Zhang Z, Yang Y, Deng F
I/C
extra-short implants (≤ 6 mm), longer implants (≥ 8 mm)
O
bone augmentation
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
children 2 to 18 years of age
I/C
systematic review of English-language articles published between January 1, 2009 and December 31, 2019, subgroups based on age, residential area, and HDI
O
prevalence of stunting as an indicator of chronic malnutrition in the MENA region
P
gynecological cancer
I/C
18 F-FDG PET, management of patients with recurrent gynecological cancers
O
changes in management
P
WHO Unity Studies Household Transmission Investigations
I/C
First Few X cases, HHTIs, crude data
O
hSAR, 95% confidence intervals
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens